March 20, 2026

Gastroparesis Treatment Market Size to Reach USD 10.45 Billion by 2034

The global gastroparesis treatment market size is estimated to reach around USD 10.45 billion by 2034 increasing from USD 6.63 billion in 2024, with a CAGR of 4.65%.
Gastroparesis Treatment Market Size 2025 to 2034

Market Overview

The Gastroparesis Treatment Market is rapidly evolving, focusing on innovative therapies designed to manage delayed gastric emptying and associated symptoms. The Gastroparesis Therapy Market encompasses a variety of treatment modalities, including pharmacological agents, gastric electrical stimulation devices, and dietary management products. Increasing prevalence of gastroparesis due to diabetes and other chronic conditions is driving market expansion globally. Healthcare providers are adopting multidisciplinary approaches to improve patient quality of life, supporting growth in this market segment.

AI and Innovation

Artificial intelligence is becoming a pivotal component in the Gastroparesis Treatment Market by enabling personalized treatment plans and improving diagnostic accuracy. In the Gastroparesis Therapy Market, AI-powered tools assist in analyzing patient data to tailor therapies and monitor treatment efficacy. Innovation includes the development of novel drug delivery systems and smart implantable devices that offer targeted stimulation to enhance gastric motility. These technological advancements aim to improve therapeutic outcomes while reducing side effects.

Future Trends of Market

Future trends in the Gastroparesis Treatment Market point toward an increased use of biologics and regenerative medicine techniques. The Gastroparesis Therapy Market is expected to witness growth in minimally invasive interventions and combination therapies that enhance gastric function. Emerging research on microbiome modulation and gene therapy also holds promise. Digital health technologies and remote patient monitoring will further transform treatment paradigms, increasing patient adherence and follow-up care efficiency.

Rising Demands of Market

Rising demand in the Gastroparesis Treatment Market is driven by growing awareness of gastroparesis symptoms and improved diagnostic methods. The Gastroparesis Therapy Market benefits from an aging population and the rising incidence of diabetes, which is a major risk factor. Increased availability of treatment options and patient education contribute to greater therapy adoption. As healthcare infrastructure improves, more patients are seeking effective treatments, fueling market growth.

Key Market Highlights

Key highlights of the Gastroparesis Treatment Market include recent regulatory approvals of new pharmacological agents and advanced neurostimulation devices. The Gastroparesis Therapy Market has seen significant investment in R&D to develop innovative drug formulations with better safety profiles. Strategic collaborations between pharmaceutical companies and medical device manufacturers have accelerated product development. Expansion of reimbursement policies and awareness campaigns are further boosting market traction.

Market Growth Drivers

The Gastroparesis Treatment Market is primarily driven by the rising prevalence of diabetes and other chronic diseases linked to delayed gastric emptying. The Gastroparesis Therapy Market also benefits from advancements in diagnostic imaging and motility testing technologies. Increasing healthcare expenditure and favorable insurance coverage enhance patient access to treatments. Growing demand for non-invasive and effective therapies supports sustained market growth worldwide.

Restraints

Despite its growth potential, the Gastroparesis Treatment Market faces challenges such as high treatment costs and limited availability of specialized care centers. The Gastroparesis Therapy Market is also constrained by the side effects associated with some pharmacological treatments, which may affect patient compliance. Regulatory complexities and lengthy approval processes can delay market entry for new therapies. Additionally, lack of awareness in certain regions hampers early diagnosis and treatment.

Opportunities

Opportunities in the Gastroparesis Treatment Market include expanding access in emerging economies with increasing healthcare investments. The Gastroparesis Therapy Market can leverage advancements in biotechnology and medical devices to develop next-generation treatments. Increasing collaborations between research institutions and industry stakeholders offer pathways to innovation. Digital health solutions and telemedicine present new avenues for patient management and market expansion.

Also Read@ https://www.pharma-geek.com/dehydration-monitoring-devices-market/

Gastroparesis Treatment Market Companies

Gastroparesis Treatment Market Companies
  • Medtronic plc
  • Allergan plc (now part of AbbVie Inc.)
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Evoke Pharma Inc.
  • Neurogastrx, Inc.
  • Theravance Biopharma, Inc.
  • CinRx Pharma
  • Axsome Therapeutics, Inc.
  • RaQualia Pharma Inc.
  • ANI Pharmaceuticals, Inc.
  • Ironwood Pharmaceuticals, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • Processa Pharmaceuticals, Inc.
  • Neurogastrix Technologies Ltd.
  • Evoke Pharma Inc.
  • EndoStim, Inc.
  • AbbMed Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cadila Healthcare Limited

Recent Developments

  • In April 2025, Meitheal Pharmaceuticals, Inc., announced that it has received U.S. Food and Drug Administration (FDA) approval for and launched liraglutide injection (18mg/3mL), its generic equivalent for Victoza®2 in the U.S. Liraglutide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist used along with diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
  • In September 2024, Avenacy, a specialty pharmaceutical company, announced it had launched Metoclopramide Injection, USP in the United States as a therapeutic generic equivalent for Reglan® as approved by the U.S. Food and Drug Administration. Metoclopramide Injection, USP is indicated for symptoms associated with diabetic gastroparesis, nausea, and vomiting associated with emetogenic cancer chemotherapy

Get Free sample link @ https://www.precedenceresearch.com/sample/6597